The DOI matches its Crossref record.
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Open accessAbstract
The effects of anadamide, 2-arachidonoylglycerol and related compounds on the specific binding of a radiolabeled cannabinoid receptor ligand,[3H]CP55940, to synaptosomal membranes were examined. Anandamide, an endogenous cannabinoid receptor ligand, reduced the specific binding of [3H]CP55940 to synaptosomal membranes in a dose-dependent manner: the Ki value was 89 nM. 2-Arachidonoylglycerol was also shown to bind appreciably to the cannabinoid receptor in competitive inhibition experiments. The apparent binding affinity was markedly increased when the binding assay was carried out in the presence of the esterase inhibitor DFP or at 0 degrees C. Free arachidonic acid and N-palmitoylethanolamine were almost inactive in terms of binding to the cannabinoid receptor in synaptosomal membranes. 2-Arachidonoylglycerol may be an endogenous cannabinoid receptor ligand in the brain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most studied endogenous ligands that bind cannabinoid receptors are AEA (Devane et al, 1992) and 2arachidonoylglycerol (2-AG) (Mechoulam et al, 1995;Sugiura et al, 1995).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Sugiura et al, 1995
Citations
Cited by
Sorted by citations
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Marzo, V. D., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,666
Role of Endogenous Cannabinoids in Synaptic Signaling
Freund, T. F., Katona, I., & Piomelli, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,616
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,514
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,526
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,448
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A., Selley, D. E., Parsons, L. H., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.129 · Cited by 954
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 891
Ohno‐Shosaku, T., Maejima, T., & Kano, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00247-1 · Cited by 874
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704767 · Cited by 788
ENDOCANNABINOID-MEDIATED SYNAPTIC PLASTICITY IN THE CNS
Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112834 · Cited by 829
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M. A., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 782
Postsynaptic endocannabinoid release is critical to long-term depression in the striatum
Gerdeman, G. L., Ronesi, J. A., & Lovinger, D. M. (2002) · Nature Neuroscience · doi:10.1038/nn832 · Cited by 795
2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptor
Hanuš, L., Abu‐Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I. M., & Mechoulam, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061029898 · Cited by 761
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben‐Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
Endocannabinoid control of food intake and energy balance
Marzo, V. D., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 764
Iversen, L. L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 751
Butler, R. K., & Finn, D. P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.003 · Cited by 768
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Marzo, V. D., Melck, D. J., Bisogno, T., & PETROCELLIS, L. D. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 722
LPA receptor signaling: pharmacology, physiology, and pathophysiology
Yung, Y. C., Lummis, N. C., & Chun, J. J. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046458 · Cited by 729
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1188 · Cited by 721
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L. M., Franklin, A., Witting, A., Wade, C. B., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 674
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 698
Overton, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C. T., Gardner, L. S., Griffin, G., Jackson, H. C., Procter, M. J., Rasamison, C. M., Tang‐Christensen, M., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.004 · Cited by 670
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Marzo, V. D., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 677
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system
Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2616 · Cited by 641
Ben‐Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., Bisogno, T., PETROCELLIS, L. D., Marzo, V. D., & Mechoulam, R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00392-6 · Cited by 650
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
CB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 659
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores.
Zechner, R., Kienesberger, P. C., Haemmerle, G., Zimmermann, R., & Lass, A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800031-jlr200 · Cited by 576
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanus, L. O., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 581
Farooqui, A. A., Horrocks, L. A., & Farooqui, T. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00128-6 · Cited by 555
Maejima, T., Hashimoto, K., Yoshida, T., Aiba, A., & Kano, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00375-0 · Cited by 575
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Marzo, V. D., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 538
Howlett, A. C. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00060-6 · Cited by 562
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses
Katona, I., Urbán, G. M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., & Freund, T. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0309-06.2006 · Cited by 511
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 518
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
Richardson, J. D., Kilo, S., & Hargreaves, K. (1998) · Pain · doi:10.1016/s0304-3959(97)00213-3 · Cited by 501
Review of the Endocannabinoid System
Lu, H., & Mackie, K. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.016 · Cited by 578
New approaches and challenges to targeting the endocannabinoid system
Marzo, V. D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 502
Modulation of the cannabinoid CB 2 receptor in microglial cells in response to inflammatory stimuli
Maresz, K., Carrier, E. J., Ponomarev, E. D., Hillard, C. J., & Dittel, B. N. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03380.x · Cited by 490
Melis, M., Pistis, M., Perra, S., Muntoni, A. L., Pillolla, G., & Gessa, G. L. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4503-03.2004 · Cited by 494
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
The endocannabinoid system: a general view and latest additions
PETROCELLIS, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 473
Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.021 · Cited by 472
Identification of GPR55 as a lysophosphatidylinositol receptor
Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., & Sugiura, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.078 · Cited by 460
Self-citationSvíženská, I. H., Dubový, P., & Šulcová, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.010 · Cited by 475
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_4 · Cited by 499
Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2005.11.027 · Cited by 445
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)
Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., Dasse, O. A., Monaghan, E. P., Parrott, J. A., & Putman, D. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00021.x · Cited by 451
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
Mechoulam, R., Fride, E., & Marzo, V. D. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00649-9 · Cited by 447
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 434
The endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Sánchez, C., CEBALLOS, M. L. D., del Pulgar, T. G., Rueda, D., Corbacho, C., Velasco, G., Galve‐Roperh, I., Huffman, J. W., y Cajal, S. R., & Guzmán, M. (2001) · PubMed · Cited by 422
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 434
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
PETROCELLIS, L. D., Melck, D. J., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., & Marzo, V. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8375 · Cited by 412
The neurobiology and evolution of cannabinoid signalling
Elphick, M. R., & Egertová, M. (2001) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2000.0787 · Cited by 427
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 435
Varga, K., Wagner, J. A., Bridgen, D. T., & Kunos, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.11.1035 · Cited by 411
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
de Fonseca, F. R., del Arco, I., Bermúdez‐Silva, F. J., Bilbao, A., Cippitelli, A., & Navarro, M. (2004) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 419
Marzo, V. D., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 394
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
Long, J. Z., Nomura, D. K., Vann, R. E., Walentiny, D. M., Booker, L., Jin, X., Burston, J. J., Sim‐Selley, L. J., Lichtman, A. H., Wiley, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909411106 · Cited by 405
Evidence for novel cannabinoid receptors
Begg, M., Pacher, P., Bátkai, S., Osei‐Hyiaman, D., Offertáler, L., Mo, F.-M., LIU, J., & Kunos, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.005 · Cited by 396
Endocannabinoid signalling and the deteriorating brain
Marzo, V. D., Stella, N., & Zimmer, A. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3876 · Cited by 395
Uchigashima, M., Narushima, M., Fukaya, M., Katona, I., Kano, M., & Watanabe, M. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0448-07.2007 · Cited by 375
CB 1 and CB 2 Receptor Pharmacology
Howlett, A. C., & Abood, M. E. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.03.007 · Cited by 411
Towards the use of cannabinoids as antitumour agents
Velasco, G., Sánchez, C., & Guzmán, M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3247 · Cited by 395
Gonsiorek, W., Lunn, C. A., Fan, X., Narula, S. K., Lundell, D. J., & Hipkin, R. W. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26516-0 · Cited by 376
Bisogno, T., Melck, D. J., BOBROV, M. Y., Gretskaya, N. M., Безуглов, В. В., PETROCELLIS, L. D., & Marzo, V. D. (2000) · Biochemical Journal · doi:10.1042/bj3510817 · Cited by 389
Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., & Waku, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.605 · Cited by 373
Self-citationMarzo, V. D. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.010 · Cited by 381
Endocannabinoids and the control of energy balance
Matias, I., & Marzo, V. D. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.11.006 · Cited by 367
Hill, M. N., Patel, S., Carrier, E. J., Rademacher, D. J., Ormerod, B. K., Hillard, C. J., & Gorzalka, B. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300601 · Cited by 363
Review article: The impact of obesity on reproduction in women with polycystic ovary syndrome
Pasquali, R., Gambineri, A., & Pagotto, U. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00990.x · Cited by 359
Iannotti, F. A., Marzo, V. D., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 373
Simon, G. M., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604660200 · Cited by 360
SUGIURA, T., KISHIMOTO, S., OKA, S., & Gokoh, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 374
Self-citationThe Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 354
Metadata
- Authors
- Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K.
- Affiliations
- Teikyo University (JP)
- ORCID
- Yamashita, A.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 1995-10
- Volume
- 215
- Issue
- 1
- Pages
- 89-97
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2085741941
- Cited by
- 2,196
- References
- 0
- Citations by year
- 2026: 22 · 2025: 61 · 2024: 68 · 2023: 63 · 2022: 59 · 2021: 113 · 2020: 97 · 2019: 68 · 2018: 77 · 2017: 74 · 2016: 79 · 2015: 84 · 2014: 87 · 2013: 82 · 2012: 95
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Biochemical and Biophysical Research Communications (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- 2-arachidonoylglycerol, anandamide, endocannabinoid system, cannabinoid receptors, synaptosomal membranes, competitive inhibition, esterase inhibition, DFP, arachidonic acid, N-palmitoylethanolamine, brain
- MeSH terms
- Animals, Arachidonic Acids, Binding, Competitive, Brain, Cannabinoids, Cyclohexanols, Dose-Response Relationship, Drug, Glycerides, Lipase, Male, Receptors, Drug, Synaptic Membranes, Tritium, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review